Related Experiment Videos
Vincristine induced cranial polyneuropathy.
Ali Bay1, Cahide Yilmaz, Nebi Yilmaz
1Yuzuncu Yil University Faculty of Medicine, Division of Hematology, Van, Turkey. bayalibay@yahoo.com
Indian Journal of Pediatrics
|July 4, 2006
Summary
Vincristine chemotherapy can cause cranial polyneuropathy in children. This case study shows successful recovery from vincristine-induced ptosis using pyridoxine and pyridostigmine.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Clinical Neurology
Background:
- Acute Lymphoblastic Leukemia (ALL) is a common childhood cancer.
- Vincristine is a standard chemotherapeutic agent used in ALL treatment.
- Vincristine can induce neurotoxicity, including cranial polyneuropathy.
Observation:
- A 5-year-old girl with preB cell ALL developed bilateral ptosis after vincristine treatment.
- Neurological examination confirmed complete external ophthalmoplegia.
- The patient had received a cumulative dose of 3.8 mg of vincristine prior to symptom onset.
Findings:
- Treatment with pyridoxine and pyridostigmine was initiated for neuroprotection and regeneration.
- Marked improvement in bilateral ptosis was observed within 7 days.
- Complete resolution of ptosis occurred after two weeks of treatment.
- The treatment was well-tolerated with no reported side effects.
Implications:
- Pyridoxine and pyridostigmine may be effective in managing vincristine-induced cranial polyneuropathy in pediatric patients.
- This therapeutic approach offers a potential strategy to mitigate a common chemotherapy side effect.
- Further research is warranted to confirm the efficacy and safety of this treatment combination.